Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy

Neurourology and Urodynamics

Volumn 30, Issue 8, 2011, Pages 1525-1529

  Liu, Hsin Tzu ^a   Lin, Heng ^a   Kuo, Hann Chorng ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

Author keywords

inflammation; nerve growth factor; overactive bladder; pathophysiology

Indexed keywords

CREATININE; NERVE GROWTH FACTOR; SOLIFENACIN; TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; FEMALE; HUMAN; MALE; MICTURITION; OVERACTIVE BLADDER; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; URGE INCONTINENCE; URINARY URGENCY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CREATININE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NERVE GROWTH FACTOR; QUINUCLIDINES; SYNDROME; TAIWAN; TETRAHYDROISOQUINOLINES; TIME FACTORS; TREATMENT FAILURE; UP-REGULATION; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 80054799647     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.21118     Document Type: Article

References (33)

1. Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6: S580-90.
2. Temml C, Heidler S, Ponholzer A, et al. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol 2005; 48: 622-7.
3. Yiangou Y, Facer P, Ford A, et al. Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. BJU Int 2001; 87: 774-9.
4. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174: 977-83.
5. Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 1999; 277: C183-201.
6. Chapple CR,. Muscarinic receptor antagonist in the treatment of overactive bladder. Urology 2000; 55: 33-46.
7. Melville JL, Walker E, Katon W, et al. Prevalence of comorbid psychiatric illness and its impact on symptom perception, quality of life, and functional status in women with urinary incontinence. Am J Obstet Gynecol 2002; 187: 80-7.
8. Rodríguez MA, Afari N, Buchwald DS,. National Institute of Diabetes and Digestive and Kidney Diseases Working Group on urological chronic pelvic pain. Evidence for overlap between urological and nonurological unexplained clinical conditions. J Urol 2009; 182: 2123-31.
9. Steers WD,. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 2002; 4: S7-18.
10. Alleva E, Santucci D,. Psychosocial vs. "physical" stress situations in rodents and humans: role of neurotrophins. Physiol Behav 2001; 73: 313-20.
11. Lowe EM, Anand P, Terenghi G, et al. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol 1997; 79: 572-7.
12. Kim JC, Kim DB, Seo SI, et al. Nerve growth factor and vanilloid receptor expression, and detrusor instability, after relieving bladder outlet obstruction in rats. BJU Int 2004; 94: 915-8.
13. Birder LA, Wolf-Johnston A, Griffiths D, et al. Role of urothelial nerve growth factor in human bladder function. Neurourol Urodyn 2007; 26: 405-9.
14. Vizzard MA,. Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol 2000; 161: 273-84.
15. Seki S, Sasaki K, Igawa Y, et al. Detrusor overactivity induced by increased levels of nerve growth factor in bladder afferent pathways in rats. Neurourol Urodyn 2003; 22: 375-7.
16. Okragly AJ, Niles AL, Saban R, et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J Urol 1999; 161: 438-42.
17. Liu HT, Kuo HC,. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 2008; 179: 2270-4.
18. Liu HT, Kuo HC,. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology 2008; 72: 104-8.
19. Liu HT, Chancellor MB, Kuo HC,. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int 2008; 102: 1440-4.
20. Liu HT, Chancellor MB, Kuo HC,. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 2009; 56: 700-6.
21. Liu HT, Tyagi P, Chancellor MB, et al. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int 2009; 104: 1476-81.
22. Kuo HC, Liu HT, Tyagi P, et al. Urinary nerve growth factor levels in urinary tract diseases with or without frequency urgency symptoms. LUTS 2010; 2: 88-94.
23. Liu HT, Liu AB, Chancellor MB, et al. Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident. BJU Int 2009; 104: 1158-62.
24. Liu HT, Chancellor MB, Kuo HC,. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 2009; 103: 1668-72.
25. Bonini S, Lambiase A, Bonini S, et al. Nerve growth factor: an important molecule in allergic inflammation and tissue remodeling. Int Arch Allergy Immunol 1999; 118: 159-62.
26. Bonini S, Lambiase S, Bonini F, et al. Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma. Proc Natl Acad Sci USA 1996; 93: 10955-60.
27. Serrano-Sánchez T, Robinson-Agramonte MA, Lorigados-Pedre L,. Endogenous nerve growth factor in patients with Alzheimer s disease. Rev Neurol 2001; 32: 825-8.
28. Stanzani L, Zoia C, Sala G, et al. Nerve growth factor and transforming growth factor-beta serum levels in acute stroke patients. Possible involvement of neurotrophins in cerebrovascular disease. Cerebrovasc Dis 2001; 12: 240-4.
29. Brown JS, McGhan WF, Chokroverty S,. Comorbidities associated with overactive bladder. Am J Manage Care 2000; 6: S574-9.
30. Steers WD, Tuttle JB,. Mechanisms of diseases: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 2006; 3: 101-10.
31. Lang UE, Gallina J, Danker-Hopfe H, et al. Nerve growth factor serum concentrations in healthy human volunteers: physiological variance and stability. Neurosci Lett 2003; 344: 13-6.
32. Serrano T, Lorigados LC, Armenteros S,. Nerve growth factor levels in normal human sera. NeuroReport 1996; 8: 179-81.
33. Orita S, Ohtori S, Nagata M, et al. Inhibiting nerve growth factor or its receptors downregulates calcitonin gene-related peptide expression in rat lumbar dorsal root ganglia innervating injured intervertebral discs. J Orthop Res 2010; 28: 1614-20.